Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that now seem to have the weight-loss drug market to themselves. Shares of Eli Lilly(NYSE: LLY) were down 2.8% today, and Novo Nordisk(NYSE: NVO) lost 4%. A simpler dosage method This morning, Roche announced results of its new GLP-1 drug trial showing patients losing an average of 7.3% of their body weight after four weeks of treatment, which it calls a "clinically meaningful weight loss." Even better for patients, the drug comes in the form of a pill taken once daily. This isn't great news for Lilly and Novo Nordisk, both of which have blockbuster GLP-1 drugs on the market -- Zepbound and Mounjaro for Lilly, and Ozempic and Wegovy for Novo Nordisk. Some patients are obviously going to prefer a weight loss drug in pill form, so Roche's CT-996 poses a clear and present danger to the other two companies' future profits. Is Roche stock a buy? Roche's GLP-1 drug is still at a very early stage in its development. And its two main competitors are working on putting their own weight loss drugs in pill form, too, which will mitigate the risk to their profits. Even so, adding Roche to the mix means profits in this sector will get divvied up among more players, probably depressing profit margins for all involved. The biggest risk for Lilly and Novo Nordisk investors, though, is in competition on the stock market. Roche stock at 19.5 times earnings is going to look a lot more attractive to investors focused on value (and growth) than Novo Nordisk at 47 times earnings or Eli Lilly at 135 times earnings. Should you invest $1,000 in Roche Ag right now? Before you buy stock in Roche Ag, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Roche Ag wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $774,281!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of July 15, 2024 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Roche Ag. The Motley Fool has a disclosure policy. Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped was originally published by The Motley Fool
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...